TSRI team finds potential drug candidates that could intervene in deadly diseases
(Scripps Research Institute) In a new study, scientists at The Scripps Research Institute have identified drug candidates that can boost a cell's ability to catch the 'typos' in protein production that can cause a deadly disease called amyloidosis, revealing a new approach to intervene in human disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 20, 2016 Category: Global & Universal Source Type: news

Bortezomib-Based Chemo Ups AL Cardiac Amyloidosis SurvivalBortezomib-Based Chemo Ups AL Cardiac Amyloidosis Survival
Heart failure due to light-chain amyloidosis is "one of the most devastating diagnoses a cardiologist may give a patient," one expert observes. Heartwire from Medscape (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 29, 2016 Category: Consumer Health News Tags: Cardiology News Source Type: news

Diabetes drugs may be useful for Alzheimer's, mice research finds
Conclusion Both Alzheimer's disease and diabetes seem to have become more common in recent years, causing illness and putting strain on the health service. News that the two illnesses may have a common cause raises hopes that drugs which help with one disease may also be of use in treating another. Trials of a diabetes drug on people with Alzheimer's disease are reported to be underway, although no results have been published yet. This study, suggesting a mechanism which may be involved in the early stages of both diseases, may increase the likelihood that common treatments will be useful. The study's main limitation is th...
Source: NHS News Feed - June 22, 2016 Category: Consumer Health News Tags: Neurology Mental health Diabetes Source Type: news

Calling All Researchers: Submit Your Grant Applications for the 2016 Brian D. Novis Research Awards
The Brian D. Novis Research Awards honor the IMF's founder Brian Novis, who died of multiple myeloma in July of 1992. The awards go to researchers doing work in the field of multiple myeloma and related disorders including smoldering myeloma, MGUS (monoclonal gammopathy of undetermined significance), as well as immunoglobulin-derived amyloidosis. The 2016 awards are $50,000 each for junior grants and $80,000 for senior grants. August 1, 2016 is the deadline for applications. For more information and grant applications, click HERE. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - May 27, 2016 Category: Hematology Source Type: news

Amyloidosis
Title: AmyloidosisCategory: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 5/19/2016 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - May 19, 2016 Category: Rheumatology Source Type: news

Sylvester researchers develop novel disease model to study multiple myeloma
(University of Miami Miller School of Medicine) Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have developed an animal model that allows them to better understand the mechanisms that lead to the development of multiple myeloma, a hematologic cancer of plasma cells, and the amyloidosis that sometimes accompanies it. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 5, 2016 Category: Biology Source Type: news

Protein trigger for juvenile idiopathic arthritis identified
US scientists have successfully identified a protein that plays a potentially key role in triggering juvenile idiopathic arthritis.Scientists at the Albert Einstein College of Medicine in New York have identified a human protein called transthyretin (TTR) that causes an autoimmune reaction in the joints of youngsters with this form of the disease - a discovery that could pave the way for new treatment options.The role of the TTR protein Juvenile idiopathic arthritis is the most common form of childhood arthritis and is understood to be an autoimmune disease, caused by antibodies attacking certain proteins in a person's...
Source: Arthritis Research UK - February 29, 2016 Category: Rheumatology Source Type: news

Leading efforts to better understand amyloidosis diseases
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no less key to a healthy dialogue on issues in health care today. We’re pleased to host a guest blog from Isabelle Lousada, president and CEO of the Amyloidosis Research Consortium. (Source: The Catalyst)
Source: The Catalyst - February 26, 2016 Category: Pharmaceuticals Authors: Guest Contributor Tags: Rare Diseases & Rare Disease Day Source Type: news

Karmanos’ Myeloma and Amyloidosis team receives prestigious award for contributions to multiple myeloma research
(Source: Karmanos Cancer Institute)
Source: Karmanos Cancer Institute - February 19, 2016 Category: Cancer & Oncology Source Type: news

Karmanos ’ Myeloma and Amyloidosis team receives prestigious award for contributions to multiple myeloma research
(Source: Karmanos Cancer Institute)
Source: Karmanos Cancer Institute - February 19, 2016 Category: Cancer & Oncology Source Type: news

Astrocytes implicated in preclinical AD
Astrocytes are activated in the brains of people with autosomal dominant Alzheimer’s disease long before symptoms appear and even before amyloidosis begins, a study shows. (Source: MedWire News)
Source: MedWire News - February 13, 2016 Category: Consumer Health News Tags: Alzheimer ' s disease Source Type: news

Discovery: Molecular mechanism at root of familial amyloidosis and other diseases
A team of local researchers has proposed a molecular mechanism that may be responsible for the development of life-threatening diseases called amyloidoses. (Source: Parkinson's Disease News From Medical News Today)
Source: Parkinson's Disease News From Medical News Today - November 13, 2015 Category: Neurology Tags: Alzheimer's / Dementia Source Type: news

Molecular mechanism at root of familial amyloidosis and other diseases
A team of local researchers has proposed a molecular mechanism that may be responsible for the development of life-threatening diseases called amyloidoses. The best known of such diseases is Alzheimer's disease, but there are many others that are receiving increased scrutiny, in part because of mounting evidence linking them to atherosclerosis and aging. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 12, 2015 Category: Science Source Type: news

Predicting Progressive Atrophy in Mild Cognitive ImpairmentPredicting Progressive Atrophy in Mild Cognitive Impairment
Dr Barclay reviews a study aiming to determine how beta-amyloidosis and neurodegeneration predict regional progression of hypometabolism and atrophy in patients with mild cognitive impairment. Medscape Neurology (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - November 5, 2015 Category: Neurology Tags: Neurology & Neurosurgery Viewpoint Source Type: news

Prothena to Initiate PRONTO, a Global Trial of NEOD001 in Patients With AL Amyloidosis With Primary Endpoint of Cardiac Response
(Source: Medical News (via PRIMEZONE))
Source: Medical News (via PRIMEZONE) - October 15, 2015 Category: Pharmaceuticals Source Type: news

High dose chemo & stem cell transplantation results in long-term survival for amyloid patients
(Boston University Medical Center) Patients with Light-chain amyloidosis who are treated with high-dose chemotherapy and autologous (one's own) stem cell transplantation (HDM/SCT) have the greatest success for long-term survival. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 8, 2015 Category: Cancer & Oncology Source Type: news

Light Chain Amyloidosis No Systemic Threat (CME/CE)
(MedPage Today) -- Thorough initial evaluation, long-term follow-up essential (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 25, 2015 Category: Hematology Source Type: news

A Predictor of Early Cognitive Decline A Predictor of Early Cognitive Decline
A new study looks at the relationship between cerebral amyloidosis and cognitive decline in patients with autosomal dominant Alzheimer disease. Medscape Neurology (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 16, 2015 Category: Neurology Tags: Neurology & Neurosurgery Viewpoint Source Type: news

Brain's Ability to Clear Amyloid Declines With AgeBrain's Ability to Clear Amyloid Declines With Age
The aging brain takes longer to clear amyloid-beta, a new study shows, which may explain why risk for the disease increases with age. It may also in the future allow risk prediction for Alzheimer's and amyloidosis. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - August 19, 2015 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Alnylam begins patisiran’s Apollo-Ole trial for ATTR amyloidosis
Alnylam Pharmaceuticals has started the Phase III open-label extension study (Apollo-Ole) with patisiran, an investigational RNAi therapeutic targeting transthyretin (TTR) to treat TTR-mediated amyloidosis (ATTR amyloidosis) in patients with familial… (Source: Drug Development Technology)
Source: Drug Development Technology - July 21, 2015 Category: Pharmaceuticals Source Type: news

Two-Step Tx Shows Promise in Systemic Amyloidosis (CME/CE)
(MedPage Today) -- Significant declines in liver stiffness with an anti-amyloid monoclonal antibody. (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - July 15, 2015 Category: Gastroenterology Source Type: news

Molecular Heart Imaging Could Spot Cardiac AmyloidosisMolecular Heart Imaging Could Spot Cardiac Amyloidosis
Myocardial scintigraphy with the bone radiotracer technetium-99m hydroxymethylene diphosphonate has prognostic value for patients with transthyretin-type amyloidosis, new research suggests. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 9, 2015 Category: Consumer Health News Tags: Radiology News Source Type: news

Localized Amyloidosis Carries Low Risk of Progression to Systemic DiseaseLocalized Amyloidosis Carries Low Risk of Progression to Systemic Disease
The prognosis for patients with localized amyloidosis appears to be good for long-term survival, but patients still need to be assessed and monitored for the more dangerous systemic amyloidosis, UK researchers report. Reuters Health Information (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - May 26, 2015 Category: Primary Care Tags: Family Medicine/Primary Care News Source Type: news

Calling All Researchers: Submit Your Grant Applications for the 2016 Brian D. Novis Research Awards
The Brian D. Novis Research Awards honor the IMF's founder Brian Novis, who died of multiple myeloma in July of 1992. The awards go to researchers doing work in the field of multiple myeloma and related disorders including smoldering myeloma, MGUS (monoclonal gammopathy of undetermined significance), as well as immunoglobulin derived amyloidosis. The 2016 awards are $50,000 each for junior grants and $80,000 for senior grants. August 3, 2015 is the deadline for applications. For more information and grant applications click HERE. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - April 23, 2015 Category: Hematology Source Type: news

Consumer Information on: Lixelle Beta 2-microglobulin Apheresis Column - H130001
The Lixelle Beta 2-microglobulin Apheresis Column (Lixelle Column) is a device that treats dialysis-related amyloidosis, a complication of kidney failure. The Lixelle Column contains specialized beads that remove a protein called Beta 2-microglobulin... (Source: Food and Drug Adminstration (FDA): CDRHNew)
Source: Food and Drug Adminstration (FDA): CDRHNew - March 19, 2015 Category: Medical Equipment Source Type: news

FDA OKs First Device for Dialysis-Related AmyloidosisFDA OKs First Device for Dialysis-Related Amyloidosis
The authorization had a special humanitarian device exemption, used for a disease or condition that affects fewer than 4000 people in the United States each year. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 11, 2015 Category: Consumer Health News Tags: Nephrology News Alert Source Type: news

UCLA study shows feasibility of blood-based test for diagnosing Alzheimer’s Disease
UCLA researchers have provided the first evidence that a simple blood test could be developed to confirm the presence of beta amyloid proteins in the brain, which is a hallmark of Alzheimer’s disease. Although approximately 5 million Americans are living with Alzheimer’s, no reliable blood-based test currently exists for the neurodegenerative disorder that is the sixth-leading cause of death in the United States. Using blood-based biomarkers — a signature of proteins in the blood that indicate the presence of a disease — to diagnose Alzheimer’s could be a key advance. “Blood-based biomar...
Source: UCLA Newsroom: Health Sciences - March 11, 2015 Category: Universities & Medical Training Source Type: news

FDA Authorizes Use Of First Device To Treat Patients With Dialysis-Related Amyloidosis
The U.S. Food and Drug Administration recently authorized use of Lixelle Beta 2-microglobulin Apheresis Column, the first device to treat dialysis-related amyloidosis (DRA). (Source: Medical Design Online News)
Source: Medical Design Online News - March 10, 2015 Category: Medical Equipment Source Type: news

First Device Approved for Dialysis-Related Amyloidosis
Title: First Device Approved for Dialysis-Related AmyloidosisCategory: Health NewsCreated: 3/6/2015 12:00:00 AMLast Editorial Review: 3/9/2015 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - March 9, 2015 Category: Rheumatology Source Type: news

FDA authorizes use of first device to treat patients with dialysis-related amyloidosis
The U.S. Food and Drug Administration today authorized use of Lixelle Beta 2-microglobulin Apheresis Column, the first device to treat dialysis-related amyloidosis (DRA). (Source: Food and Drug Administration)
Source: Food and Drug Administration - March 6, 2015 Category: American Health Source Type: news

Amyloid formation may link Alzheimer disease and type 2 diabetes
The pathological process amyloidosis, in which misfolded proteins (amyloids) form insoluble fibril deposits, occurs in many diseases, including Alzheimer disease (AD) and type 2 diabetes mellitus (T2D). However, little is known about whether different forms of amyloid proteins interact or how amyloid formation begins in vivo. A new study has found evidence that amyloid from the brain can stimulate the growth of fibrils in the murine pancreas and pancreatic-related amyloid can be found along with brain-related amyloid in human brain senile plaques. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 17, 2015 Category: Science Source Type: news

Amyloid formation may link Alzheimer disease and type 2 diabetes
(Elsevier Health Sciences) The pathological process amyloidosis, in which misfolded proteins (amyloids) form insoluble fibril deposits, occurs in many diseases, including Alzheimer disease and type 2 diabetes. A study published in The American Journal of Pathology has found evidence that amyloid from the brain can stimulate the growth of fibrils in the murine pancreas and pancreatic-related amyloid can be found along with brain-related amyloid in human brain senile plaques. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 17, 2015 Category: Global & Universal Source Type: news

ASH: New Myeloma Regimens, AL Amyloidosis (CME/CE)
(MedPage Today) -- Add-on therapy with HDAC inhibitor improved outcomes in myeloma. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - December 15, 2014 Category: Consumer Health News Source Type: news

Prothena targets rare protein-misfolding disease in late-stage study
Elan Corp. spinout Prothena Corp. will take an experimental drug aimed at a rare protein-misfolding disease into a late-stage clinical trial, the company said Tuesday. Prothena (NASDAQ: PRTA), whose operations are largely based in South San Francisco, said it will focus its drug on amyloid light-chain amyloidosis, or AL amyloidosis, in what's expected to be a 230-patient, Phase III study. In the disease, misfolded amyloid proteins are deposited in tissue, causing progressive organ damage, including… (Source: bizjournals.com Health Care:Hospitals headlines)
Source: bizjournals.com Health Care:Hospitals headlines - December 2, 2014 Category: Hospital Management Authors: Ron Leuty Source Type: news

MRI and LV Remodelling in Cardiac AmyloidosisMRI and LV Remodelling in Cardiac Amyloidosis
Learn more about the morphological features and remodelling patterns of cardiac amyloidosis as seen with cardiac magnetic resonance imaging. Heart (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 20, 2014 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Alnylam begins DISCOVERY trial to track TTR mutation prevalence
Alnylam Pharmaceuticals has started the DISCOVERY trial of its investigational candidate ALN-TTRsc, to evaluate the prevalence of transthyretin (TTR) mutations in patients suspected of cardiac amyloidosis. (Source: Drug Development Technology)
Source: Drug Development Technology - September 25, 2014 Category: Pharmaceuticals Source Type: news

Hysterectomy Association Newsletter September 2014
Sourced from The Hysterectomy Association: Hysterectomy Association - Hysterectomy Association - hysterectomy, menopause and hormone replacement therapy (hrt) information and support for women. Welcome to the September newsletter. Well, my dire predictions of the summer ending thankfully didn’t come to anything and we seem to be enjoying a late summer bonus here in the UK. Hopefully that’s the case elsewhere in the world too. The Hysteria Writing Competition has finally closed to entries for this year and our judges are busy finishing off reading all the entries that arrived in the last week of August. When our...
Source: The Hysterectomy Association - September 11, 2014 Category: OBGYN Authors: Linda Parkinson-Hardman Tags: Newsletters Amyloidosis sleeping Source Type: news

Cardiac Amyloidosis: The Great ImitatorCardiac Amyloidosis: The Great Imitator
Three Mayo experts explain the three main types of cardiac amyloidosis and dispel some myths about the diagnosis and treatment of this rare condition. Mayo Clinic (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 8, 2014 Category: Cardiology Tags: Cardiology Roundtable Source Type: news

Amyloidosis – Can you help relieve the pressure?
Sourced from The Hysterectomy Association: Hysterectomy Association - Hysterectomy Association - hysterectomy, menopause and hormone replacement therapy (hrt) information and support for women. Have you ever heard of amyloidosis? Don’t worry, I hadn’t either! The good news is you don’t have to be an expert on this rare and dangerous disease to help lighten the load of its victims. Amyloidosis is a condition which causes an excessive build-up of proteins in the blood. These proteins form clusters called ‘amyloids’, which are deposited around the sufferer’s body, putting undue pressure on ...
Source: The Hysterectomy Association - September 2, 2014 Category: OBGYN Authors: Linda Parkinson-Hardman Tags: Health Conditions Amyloidosis invisible illness Source Type: news

Cajal-Retzius cell loss and amyloidosis in Alzheimer's disease
(Neural Regeneration Research) Cajal-Retzius cells are reelin-secreting neurons in the marginal zone of the neocortex and hippocampus. However, the relationship between Cajal-Retzius cells and Alzheimer's disease is unknown. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 5, 2014 Category: Biology Source Type: news

Widely-used anti-inflammatory drug shows success in treatment of amyloidosis
This study, published in the Dec. 25 issue of JAMA, is one of the first examples of successful repurposing of a generic drug to treat a rare disease. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 30, 2013 Category: Consumer Health News Tags: Neurology / Neuroscience Source Type: news

Widely-used anti-inflammatory drug shows success in treatment of amyloidosis
(Boston University Medical Center) A recent study led by researchers from the Amyloidosis Center at Boston University School of Medicine and Boston Medical Center demonstrates that diflunisal, a generic anti-inflammatory drug, successfully reduced neurological decline and preserved the quality of life in patients with familial transthyretin amyloidosis. Diflunisal is an inexpensive and safe medication marketed over the past 40 years for arthritis and pain. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - December 24, 2013 Category: Global & Universal Source Type: news

Alnylam starts Phase II study of ALN-TTRsc for treatment of TTR-mediated amyloidosis
US-based Alnylam Pharmaceuticals has started a pilot Phase II trial with ALN-TTRsc, a subcutaneously delivered RNAi therapeutic targeting the transthyretin (TTR) gene in development for the treatment of TTR-mediated amyloidosis (ATTR). (Source: Drug Development Technology)
Source: Drug Development Technology - December 18, 2013 Category: Pharmaceuticals Source Type: news

Familial amyloidosis modeled in vitro using iPSC technology
Researchers from Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) have generated the first known disease-specific induced pluripotent stem cell (iPSC) lines from a patient with familial transthyretin amyloidosis (ATTR). The findings, which are reported in Stem Cell Reports, may lead to new treatments for genetic diseases such as familial amyloidosis. iPSCs are a form of stem cells that come from skin or blood cells reprogrammed into cells that have the ability to become any type of tissue in the body... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 5, 2013 Category: Consumer Health News Tags: Stem Cell Research Source Type: news

Diagnosis: The Tell-Tale Green Heart
A very odd finding during routine surgery helps explain everything.     (Source: NYT Health)
Source: NYT Health - November 1, 2013 Category: Consumer Health News Authors: By LISA SANDERS, M.D. Tags: Heart Amyloidosis Surgery and Surgeons Source Type: news

Alnylam completes enrolment in Phase II Transthyretin-Mediated Amyloidosis clinical trial
Alnylam Pharmaceuticals has completed enrolment in its Phase II trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis (ATTR). (Source: Drug Development Technology)
Source: Drug Development Technology - October 2, 2013 Category: Pharmaceuticals Source Type: news

Biomarker IDs Fibrotic Heart Failure (CME/CE)
ORLANDO (MedPage Today) -- Galectin-3 (Gal-3), a biomarker for fibrosis, may have a role in identifying heart failure caused by cardiac amyloidosis, researchers suggested. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 24, 2013 Category: Cardiology Source Type: news

Experimental Drug Shows Promise for Rare Genetic Disorder
New therapy may combat amyloidosis, the potentially deadly disease caused by protein build-up in organs (Source: WebMD Health)
Source: WebMD Health - August 29, 2013 Category: Consumer Health News Source Type: news

Novel Approach to Amyloidosis Looks Promising (CME/CE)
(MedPage Today) -- An amyloidosis therapeutic strategy based on controlling gene expression passed a proof-of-concept test, suppressing transthyretin production in patients with transthyretin amyloidosis, investigators reported. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 29, 2013 Category: Cardiology Source Type: news

Experimental Drug Shows Promise for Rare Genetic Disorder
New therapy may combat amyloidosis, the potentially deadly disease caused by protein build-up in organs Source: HealthDay Related MedlinePlus Page: Amyloidosis (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - August 29, 2013 Category: Consumer Health News Source Type: news